Derek Appleton, 60 lost 11 litres of blood and went into cardiac arrest during liver surgery.
Striking doctors warn staff will leave NI for better pay
A full 24-hour strike began at 07:00 GMT – the second such action taken by doctors this year.
Experimental compound burns fat without sacrificing muscle

A new approach to weight loss could help the body burn more fat while preserving muscle, potentially overcoming one of the major drawbacks of existing obesity treatments. Researchers at the University of California, Berkeley, have identified a compound that increases the amount of energy the body uses rather than simply reducing how much food a person eats.
In experiments with mice, the compound improved blood sugar regulation, reduced harmful blood fats, and helped obese animals lose fat without a significant reduction in lean muscle mass. It also increased energy expenditure by up to 18%, even though the mice did not become more physically active or experience an increase in body temperature.
The findings, published in Science Advances, suggest a promising new direction for treating obesity, diabetes, and fatty liver disease. The experimental compound also appeared to enhance the benefits of popular weight-loss medications such as Ozempic and Wegovy when the treatments were used together. However, its effectiveness and safety have not yet been established in humans.
A Different Approach to Weight Loss Than Ozempic
Over the past five years, medications known as GLP-1 drugs have transformed the treatment of obesity and other metabolic conditions, including diabetes and fatty liver disease. Drugs marketed as Ozempic, Wegovy, Mounjaro, and Zepbound have helped many patients achieve substantial weight loss while improving their ability to regulate blood sugar.
Despite these benefits, the medications have important limitations. Nausea and other digestive problems can make treatment difficult for some patients. Because these drugs reduce appetite and food consumption, they can also increase the risk of inadequate nutrition and loss of muscle mass. Over time, losing too much muscle can contribute to weakness, frailty, and other health complications.
Berkeley researchers wanted to investigate a fundamentally different strategy. Rather than focusing on reducing calorie intake, they explored whether it would be possible to increase the amount of energy the body burns.
This process, known as energy expenditure, includes the calories used to maintain basic bodily functions, regulate metabolism, and support everyday activities. Increasing energy expenditure could potentially help people lose weight without relying exclusively on eating less.
“Body weight responds to two levers: taking in fewer calories, or spending more energy,” said Anders Näär, a professor of metabolic biology and nutrition at UC Berkeley and senior author of the study. “GLP-1s work almost entirely on the first, so we went after the second.”
A Compound That Burns Fat While Preserving Muscle
The researchers focused on a molecule called 5-tetradecyloxy-2-furoic acid (TOFA), which has an unusual combination of effects on the body’s metabolism.
TOFA interferes with the production of lipids, a broad category of fatty substances that includes cholesterol and triglycerides. These molecules serve important functions, but excessive levels of certain lipids can contribute to metabolic disorders and cardiovascular disease.
At the same time, TOFA activates genes involved in taking up and burning fat for energy. This combination allows the compound to influence both how the body produces fat and how it uses fat as fuel.
In mice, treatment with TOFA produced several encouraging results. The animals became more sensitive to insulin, the hormone that helps move glucose from the bloodstream into cells. Improved insulin sensitivity makes it easier for the body to control blood sugar, an important benefit for people with diabetes or insulin resistance.
The compound also lowered triglyceride levels and improved characteristics of fatty liver disease, a condition in which excess fat accumulates inside liver cells and can eventually interfere with liver function.
Perhaps most notably, obese mice treated with TOFA lost weight primarily through reductions in body fat, without experiencing significant losses of lean muscle mass. This distinction could be especially valuable because maintaining muscle is important for strength, mobility, and long-term metabolic health.
How TOFA Increases Energy Burning by 18%
Although TOFA was originally discovered in the 1970s, the new research uncovered additional properties that could make it particularly useful for treating metabolic disease.
The compound belongs to a group of substances known as ACC inhibitors. These compounds interfere with enzymes that help the body manufacture fatty acids, effectively slowing the production of certain fats.
Other ACC inhibitors have previously advanced to mid-stage clinical trials, but none has been approved to treat metabolic diseases. One major obstacle has been an unexpected side effect: many of these compounds increase triglycerides in the blood, potentially raising the risk of heart problems.
The Berkeley team discovered that TOFA does more than inhibit ACC. It also activates two cellular receptors called PPARα and PPARδ, which help regulate the genes responsible for fat metabolism.
These receptors function as molecular switches. When activated, they stimulate processes that allow cells to absorb fatty acids and break them down to produce energy. In effect, TOFA simultaneously reduces the production of certain fats and encourages the body to burn fat that is already available.
In mice, this activity increased energy expenditure by as much as 18%, without requiring additional physical activity or raising body temperature. Unlike other ACC inhibitors, TOFA also did not cause triglyceride levels to rise, potentially because of its additional effects on fat metabolism.
“TOFA appears to engage a coordinated metabolic response,” said study first author Justin Y. Lee, a postdoctoral student at UCSF who conducted the research as a Ph.D. student at Berkeley. “It is not simply blocking lipid synthesis. It is also activating energy expenditure pathways that may help the body handle excess lipid and glucose more effectively.”
To understand whether these effects could be reproduced with separate treatments, the scientists gave mice a combination of two different compounds. One blocked lipid production, while the other stimulated energy expenditure.
Surprisingly, this two-compound approach was less effective at improving overall metabolic health than TOFA alone. The finding suggests that TOFA’s ability to influence multiple metabolic processes through a single molecule may be an important part of its effectiveness.
Could TOFA Make Ozempic and Wegovy More Effective?
The researchers also investigated whether TOFA could improve the results of existing GLP-1 medications.
They tested the compound alongside semaglutide, the active ingredient in Ozempic and Wegovy, as well as tirzepatide, which is marketed as Mounjaro and Zepbound.
These medications primarily help people lose weight by reducing appetite and food intake. TOFA, by contrast, targets the other side of the energy balance equation by increasing how much energy the body expends.
When the researchers combined TOFA with these medications in mice, the results were more favorable than those produced by either treatment alone. The combinations led to greater improvements in body weight, blood glucose regulation, insulin levels, and triglycerides.
This suggests that treatments targeting calorie intake and energy expenditure could potentially work together to produce stronger metabolic benefits.
“In our combination experiments, TOFA worked additively or synergistically with the GLP-1 appetite-suppressing drugs, so we view it as complementary rather than as a replacement,” Näär said.
In other words, the researchers do not necessarily envision TOFA replacing medications such as Ozempic or Wegovy. Instead, it could eventually become an additional treatment that helps address obesity and related metabolic conditions through a different biological mechanism.
A Promising Discovery, but Human Trials Are Still Needed
Despite the encouraging results, the researchers emphasize that TOFA remains an experimental compound. All the findings so far come from animal studies, and scientists have not yet established whether it is safe or effective in humans.
Further research will be necessary to determine whether the same metabolic improvements can be achieved in people and whether the treatment could offer meaningful advantages over existing medications.
To help move the research toward potential clinical applications, the Berkeley scientists have established a biotechnology company called ReRx Therapeutics. The effort has received support from the university’s life sciences entrepreneurship network, including Nucleate and Berkeley SkyDeck.
If the findings eventually translate to humans, TOFA could represent an important addition to the growing range of treatments for obesity and diabetes. By encouraging the body to use more energy while helping preserve muscle, the compound points toward a potentially different way to achieve healthier weight loss.
The research was funded through discretionary resources provided by UC Berkeley, with additional support from the UCSF Liver Center and the University of Michigan Animal Phenotyping Core.
Additional authors include Chi Zhu, Melissa A. Boldridge, Rachelle L. Stark, Lei Xu, Federico Gonzalez, Xin Tang, Kaitlyn T. Dang and Kook Son of Berkeley; Gracia Bonilla, Kashish Chetal and Ruslan I. Sadreyev of Massachusetts General Hospital; Kosuke Watari and Michael Karin of the University of California, San Diego; Christina Papa and Bilal N. Sheikh of the Helmholtz Center Munich; Prabha Ibrahim of ReRx Therapeutics.
Massive hope for pancreatic cancer pill after trial saw tumours vanish
Daily pill daraxonrasib appears to shrink and possibly even eliminate tumours in some patients with one of the deadliest cancers.
Welsh NHS in strongest pre-winter position ever, says health minister
It comes as the number waiting for planned NHS treatment in Wales increases for the sixth month.
Covid inquiry report: key findings on testing, tracing and ‘the pingdemic’
Early efforts to contain coronavirus “were doomed to fail”, the public inquiry has found. Here’s what you need to know.
Scientists tested 212 plant-based foods. Every single one contained fungal toxins

Every one of 212 plant-based foods and drinks tested in a new study contained at least one naturally occurring fungal toxin, raising questions about the potential health effects of regularly consuming these products.
Researchers examined a wide selection of vegetarian and vegan products sold in the UK, including meat alternatives and dairy substitutes. They detected at least one of 19 mycotoxins in every product, and many contained multiple toxins.
Mycotoxins are poisonous substances produced by certain fungi, including molds. They can enter the food supply when agricultural crops become contaminated during growing, harvesting, or storage.
The investigation was led by scientists at the University of Parma in Italy, with contributions from Cranfield University. The researchers analyzed 212 products, including plant-based meat alternatives (PMBAs) and plant-based beverages (PBBs). The selection covered foods commonly found on supermarket shelves, such as vegan burgers, vegetarian chicken pieces, vegan sausages, and oat, almond, and soy milk.
Although the findings highlight how widespread these naturally occurring contaminants can be, the researchers also identified an important reassuring detail. Every product contained mycotoxin concentrations below recommended European Union guideline levels, which the team said reflected the high food quality standards maintained by the UK food industry.
Why Plant-Based Foods Can Contain Fungal Toxins
Many of the ingredients used to manufacture plant-based foods are particularly susceptible to fungal contamination. Grains, legumes, and seeds can encounter mold in fields or storage facilities, creating opportunities for mycotoxins to develop before the ingredients reach food manufacturers.
Unlike bacteria or viruses, mycotoxins are chemical substances produced by certain fungi. Their presence in food does not necessarily mean the product contains living mold, and detecting a toxin does not automatically mean the food is unsafe. The potential health risk depends on factors such as the type of toxin, its concentration, and how much a person consumes over time.
This distinction is especially important for people who eat plant-based products frequently. Someone whose diet regularly includes meat substitutes, dairy alternatives, grains, and legumes may encounter these substances through several different foods rather than a single source.
Could Repeated Exposure Pose Health Risks?
While the concentrations detected in the UK products were below recommended EU guidelines, researchers say the potential effects of repeated exposure deserve closer attention.
Earlier studies have suggested that consuming small amounts of mycotoxins regularly may contribute to cumulative exposure and potentially increase health risks. In other words, assessing a single product may not provide a complete picture of a person’s overall dietary exposure.
Eating one of these products occasionally is unlikely to cause problems based on the levels reported. However, a diet that relies heavily or exclusively on plant-based foods could involve repeated exposure to mycotoxins from numerous ingredients and products. Researchers say understanding the combined effects is important for evaluating possible long-term health consequences.
The severity of mycotoxin exposure varies depending on the compounds involved and the amount consumed. At sufficiently high or harmful exposure levels, certain mycotoxins can damage the liver and kidneys, interfere with normal immune system function, and increase the risk of cancer.
The new findings do not establish that the tested products cause these conditions. Instead, they provide information that scientists can use to estimate how much exposure consumers may receive through their diets and develop more accurate food safety risk assessments for the UK population.
Scientists Call for Better Monitoring of Plant-Based Ingredients
Andrea Patriarca, Senior Lecturer in Mycology at Cranfield University, emphasized that mycotoxins are a natural part of the food environment and should not discourage people from eating a varied diet. Mycology is the branch of biology devoted to studying fungi, including molds and yeasts.
“Mycotoxins occur naturally in foods and cannot be completely avoided. As consumers, we should not be frightened or deterred from enjoying a variety of products.
However, a significant concern arises when new foods enter the market, as there are currently no established regulations to monitor mycotoxins. We collaborate closely with various sectors in the food industry, from farmers to food companies, to help implement effective mycotoxin management integrated within food safety standards. The data from our research helps food safety organizations in assessing risks, particularly in complex multi-ingredient products.
We are currently collaborating with the University of Parma to evaluate the risks faced by the population based on different dietary habits. Our aim is to advise policymakers and raise awareness among vulnerable consumers.”
The researchers are particularly interested in how food safety monitoring can keep pace with the growing range of plant-based products. Foods made from multiple ingredients present additional challenges because each component may introduce different contaminants, making overall exposure more difficult to assess.
Their work also underscores the importance of monitoring raw materials throughout the food production process. Identifying and controlling contamination before ingredients are combined into finished products could help manufacturers manage potential risks more effectively.
What the Findings Mean for Plant-Based Diets
The discovery of fungal toxins in all 212 products highlights the importance of studying dietary exposure across multiple foods, rather than evaluating each product in isolation.
For consumers, the results are not a reason to abandon vegan or vegetarian foods. The concentrations measured were below recommended EU guidelines, and the researchers stress that mycotoxins cannot be completely eliminated from the food supply.
Instead, the study points to the need for continued research into how different eating habits influence exposure, particularly among people who depend heavily on plant-based products. The University of Parma and Cranfield University are continuing their collaboration to investigate these dietary patterns, identify potentially vulnerable groups, and provide evidence that can inform future food safety policies.
The research, titled “Mycotoxin contamination in plant-based beverages and meat alternatives: A survey of the UK market,” was published in the journal Food Control.
The study was conducted as part of the European Union-funded Horizon Europe FunShield4Med project (HORIZON-WIDERA-2021-ACCESS-03), Grant Agreement No 101079173.
This 6-million-year-old whale may have had the most crooked face in mammal history

A bizarre prehistoric whale that lived roughly 6 million years ago had a face so crooked that researchers initially suspected its fossilized skull had been distorted after death. Instead, its extraordinary shape was completely natural and may represent the most extreme facial asymmetry ever documented in a mammal.
Sperm whales and pygmy sperm whales are already known for having some of the strangest head shapes among mammals. While most vertebrates have bodies and skulls that are roughly symmetrical on both sides, toothed whales have evolved uneven skull structures to accommodate specialized organs responsible for producing sound and navigating through echolocation.
Now, an international team of scientists has identified an extinct pygmy sperm whale species that took this unusual anatomy to an entirely new level. Named Scaphokogia huachafo, the whale lived during the Late Miocene, between 6.3 and 5.6 million years ago, and measured approximately 2.7 meters in length. Its fossilized skull displays the most extreme facial asymmetry known in any whale or dolphin, and possibly in any mammal.
A Prehistoric Whale With an Extraordinary Skull
“Cranial asymmetry in toothed whales is directly linked to the development of fatty structures in the forehead that are involved in sound production. But in Scaphokogia huachafo, this asymmetry went far beyond the area around the blowhole. Both bony nostrils are shifted entirely to the left side of the skull, while the facial bones differ dramatically in size and position. The skull looks completely crooked,” explains Aldo Benites-Palomino, lead author of the study.
Benites-Palomino investigated the fossil during his doctoral research at the University of Zurich’s Department of Paleontology. He is currently an assistant professor at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU).
The whale’s extraordinary appearance also inspired its scientific name. The word huachafo comes from Peruvian Spanish and is commonly used to describe something excessively flashy, bizarre, extravagant, or even tacky.
“In Peru, huachafo is an everyday word for anything that is flashy, over-the-top, bizarre, extravagant or difficult to categorize aesthetically,” says Benites-Palomino.
“When we looked at the proportions of this whale – with its face strongly shifted to the left and its oversized, downward-curving snout – it broke every rule of symmetry and elegance seen in living cetaceans. Its anatomy is so extravagant and odd that huachafo seemed the perfect name for it.”
Scientists Initially Suspected the Skull Was Deformed
The remarkable fossil was originally recovered during the mid-1990s from the Pisco Formation in southern Peru. This desert region is famous among paleontologists for its exceptionally preserved fossils of ancient marine animals.
Benites-Palomino first encountered the specimen in 2015 while preparing his Bachelor’s thesis at the Museo de Historia Natural in Lima. Its dramatically uneven shape immediately raised an important question: Was the skull genuinely this crooked when the whale was alive, or had millions of years of geological pressure distorted it?
“The initial suspicion with skulls this distorted is always taphonomy – that the specimen may have been flattened or twisted by sediment pressure over millions of years,” says Benites-Palomino.
“But the sutures are fully closed, and there are no fractures, pathologies or deformations elsewhere on the skull. This was genuine biology, not a result of poor preservation.”
The findings confirmed that the extraordinary asymmetry was part of the whale’s natural anatomy, rather than damage caused by burial, fossilization, or disease.
A Bizarre Adaptation for Hunting Along the Seafloor
The whale’s unusual skull also offers clues about how it survived. Modern sperm whales typically pursue squid in deep ocean waters, but Scaphokogia huachafo appears to have followed a very different hunting strategy. Its anatomy suggests that it was highly adapted to searching for food along the bottom of shallow coastal waters.
One of its most distinctive features was a large, tube-shaped snout strengthened by dense bone and cartilage that had hardened into bone. These heavy structures served as natural ballast, moving the whale’s center of gravity forward and downward.
Its snout also pointed downward at an angle of 31 degrees relative to the rest of its skull. By reconstructing the joint connecting the skull to the first neck vertebra, known as the atlas, scientists determined that Scaphokogia could bend its head downward by as much as 55 degrees.
“The entire cranio-cervical complex is modified to point the snout directly toward the bottom,” explains Gabriel Aguirre-Fernández, co-author of the study and doctoral advisor at the University of Zurich.
“The combination of dense bone, the downward-curving snout and the flexible neck articulation allowed the animal to move directly above the seabed and feed close to the sediment.”
Researchers also believe the whale may have relied on its highly specialized echolocation system to locate prey beneath the soft sediment of coastal environments. Unlike other marine mammals that forage along the ocean floor, Scaphokogia lacked the sensitive facial whiskers or specialized visual adaptations that can help animals find food near the bottom.
Instead, its extraordinarily asymmetrical skull may have supported a sophisticated biological sonar system that allowed it to detect hidden prey.
This unusual feeding strategy represents a specialized way of life that no longer exists among modern marine mammals. As ocean conditions shifted toward the end of the Miocene, the ecological niche occupied by Scaphokogia disappeared, eventually giving way to the marine mammal communities familiar today.
The discovery provides a remarkable glimpse into how far evolution once pushed the anatomy of whales, producing a creature whose dramatically crooked face was not a deformity, but an adaptation to a vanished underwater world.
Regulator mistakenly sent complaints about doctors to newspaper
Information sent to the Times newspaper by the General Medical Council included summaries of complaints alleging antisemitism and Islamophobia against doctors.
A rare disease reveals a hidden flaw in the immune system

For decades, scientists believed they understood what caused the dangerous inflammation associated with a rare genetic disorder. Now, researchers at the Garvan Institute of Medical Research have uncovered evidence that challenges 30 years of established thinking and could open the door to a new treatment.
The condition, known as mevalonate kinase deficiency (MKD), can cause severe inflammatory episodes that are sometimes life-threatening. A new study published in Immunity identifies a previously underrecognized problem involving natural killer (NK) cells, immune cells that normally help the body eliminate infected cells.
The researchers found that these cells malfunction in people with MKD, setting off an excessive inflammatory response when infections occur. The discovery also points to a possible treatment using existing medications called JAK inhibitors, which could be particularly valuable for patients who do not respond to current therapies.
“This study has revealed a new target for this inflammatory disorder and sets the scene for future clinical studies to explore the use of JAK inhibitors or other drugs to neutralize interferon gamma in patients with MKD,” says Professor Mike Rogers, Lab Head at Garvan and senior author of the study. “This could lead to a targeted treatment that hasn’t been tried before.”
Why a Rare Immune Disease Causes Dangerous Inflammation
MKD is a lifelong condition known to affect hundreds of children and adults around the world, although researchers suspect that many people with the disorder have never been diagnosed. Patients experience recurring attacks of high fever, skin rashes, joint pain, and inflammation in the abdomen. The most serious episodes can cause potentially fatal complications.
For roughly three decades, research into the disease has largely centered on macrophages, immune cells that help coordinate the body’s inflammatory defenses. Existing treatments are designed to block an inflammatory signal released by these cells. However, approximately half of patients do not respond adequately, leaving a major need for better treatment options.
To investigate what might be missing from the prevailing explanation, the Garvan team examined blood samples from people with MKD and studied preclinical models of the disorder.
Their experiments revealed a significant defect in natural killer cells, which play an important role in the body’s early defenses against viral infections. In MKD, these cells fail to mature properly and struggle to perform one of their most important functions: destroying infected cells before an infection can spread.
The consequences go beyond an impaired ability to fight infection. When natural killer cells cannot eliminate their targets, they release large amounts of inflammatory signaling molecules, activating other parts of the immune system and potentially triggering widespread inflammation.
“We found that these immune cells are essentially misfiring,” explains Professor Rogers. “NK cells are loaded with toxic ammunition, stored in granules that are released to kill infected cells. However, in MKD these toxic granules can’t be released from NK cells and remain trapped inside. When an NK cell fails to kill its target, it compensates by shouting for help, pumping out large amounts of interferon gamma – a powerful inflammatory signal. This activates other immune cells and causes the dangerous fever and widespread inflammation seen in patients.”
Discovery Challenges 30 Years of Immune Disease Research
The findings suggest that natural killer cell dysfunction, rather than macrophage activity alone, plays a central role in driving MKD.
Dr. Marcia Munoz, Group Leader in the Rogers Lab and lead researcher on the study, says the results represent a major change in how scientists understand the disease.
“This really turns on its head 30 years of dogma about what was thought to be the underlying mechanism of disease. In MKD, the primary problem is in NK cells and not in macrophages, as previously believed,” she says.
To investigate how this cellular defect contributes to the disorder, the Garvan researchers collaborated with Professor Mariapia Degli-Esposti and scientists at Monash University.
Using preclinical models, the team established a connection between malfunctioning natural killer cells and the severe symptoms associated with MKD. Their experiments showed that when the immune system cannot clear a viral infection, the resulting inflammatory response can cause extensive damage to organs.
These results help explain why a disorder involving defective immune defenses can also produce episodes of extreme inflammation.
Existing Drug Shows Promise for a New Treatment
The discovery has already helped guide an experimental treatment approach for a severely affected infant.
Working with doctors at the Royal Children’s Hospital in Melbourne, the researchers explored whether baricitinib could reduce the excessive inflammatory signaling associated with MKD.
Baricitinib belongs to a class of medications known as JAK inhibitors. These drugs interfere with signaling pathways used by the immune system, including those involved in responses to interferon gamma. The medication is already used to treat other immune-related conditions, including rheumatoid arthritis and eczema.
Doctors added baricitinib to the infant’s existing treatment regimen and subsequently observed an improvement in the child’s condition. Inflammatory flare-ups became less frequent, and severe inflammation affecting the gastrointestinal tract began to heal.
Although the results from a single patient cannot establish whether the treatment will work more broadly, the improvement provides encouraging early evidence for a strategy that targets a different part of the inflammatory process.
The researchers believe their findings provide a foundation for future clinical studies investigating JAK inhibitors and other medications that block interferon gamma activity in patients with MKD, particularly those who have not benefited from standard treatments.
Discovery Could Help Explain Other Genetic Diseases
The potential implications extend beyond MKD itself.
Researchers have introduced the term ‘prenylopathies’ to describe a family of genetic disorders involving the same metabolic pathway affected in MKD. Early findings suggest that these related diseases may share a similar underlying problem involving natural killer cells that fail to function properly and instead generate excessive inflammatory signals.
If further studies confirm this connection, scientists may be able to identify common disease mechanisms and develop more targeted approaches to diagnosis and treatment across multiple disorders.
“Confirming this link could help end the diagnostic odyssey many patients endure for years or even decades before receiving effective treatment,” says Professor Rogers.
Professor Mike Rogers is a Conjoint Professor at St Vincent’s Clinical School, Faculty of Medicine and Health, UNSW Sydney. Dr. Marcia Munoz is a Conjoint Senior Lecturer at St Vincent’s Clinical School, Faculty of Medicine and Health, UNSW Sydney.
